Publication | Open Access
LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
59
Citations
0
References
2022
Year
Destiny-lung02 TrialMedicineImmunologyPathologyImmune Checkpoint InhibitorInterim ResultsBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLba55 TrastuzumabLung CancerMolecular Oncology
No additional data available for this publication yet. Check back later!